Review defines roles of immunosenescence and cellular senescence in rheumatoid arthritis

A peer-reviewed literature review delineates the distinct roles of immunosenescence, inflammaging, and cellular senescence in rheumatoid arthritis, highlighting that therapeutic evidence for senolytics remains confined to non-RA models.

A review published in International Immunopharmacology by researchers from the Gansu University of Traditional Chinese Medicine examined the roles of age-related immune system remodeling in rheumatoid arthritis (RA), with a focus on elderly-onset RA (EORA).

The authors distinguished between three frequently conflated terms: immunosenescence (structural and functional immune remodeling), inflammaging (systemic, low-grade inflammatory state), and cellular senescence (stable cell cycle arrest and functional remodeling).

The paper outlined how impaired immune clearance, accumulation of senescent cells, and the senescence-associated secretory phenotype (SASP) drive synovial and bone marrow microenvironment remodeling, which are linked to cartilage damage and bone loss.

The authors noted that causal evidence supporting the efficacy of senolytic interventions in RA synovitis is still primarily derived from experimental arthritis, osteoarthritis, and other non-RA disease models.

Distinguishing the unique pathways of immunosenescence, inflammaging, and cellular senescence is necessary for designing targeted clinical interventions and risk-stratifying patients with elderly-onset RA.

The review highlights a persistent translational challenge in the longevity field, where therapeutic mechanisms validated in osteoarthritis or general aging models have not yet been clinically demonstrated in autoimmune joint pathologies like RA.

For biotechnology companies targeting cellular senescence, the analysis underscores that rheumatoid arthritis represents an unvalidated clinical frontier, despite strong theoretical links to the SASP.

The emphasis on immunosenescence highlights the potential long-term value of therapeutic approaches designed to rejuvenate or modulate the aging immune system, rather than solely clearing localized senescent cells.

The initiation of preclinical or early-stage clinical studies specifically evaluating senolytics in human rheumatoid arthritis models, as opposed to generalized osteoarthritis models.